| | Class 1 Device Recall Resmed |  |
| Date Initiated by Firm | June 25, 2026 |
| Date Posted | July 28, 2026 |
| Recall Status1 |
Open3, Classified |
| Recall Number | Z-2735-2026 |
| Recall Event ID |
99304 |
| 510(K)Number | K152068 K172875 |
| Product Classification |
Ventilator, continuous, facility use - Product Code CBK
|
| Product | Resmed Astral 100/150
Resmed Astral 100/50 is a ventilator system that provides continuous or intermittent ventilatory support for patients weighing more than 11lb (5kg) who require mechanical ventilation. |
| Code Information |
Catalog Number: Astral 100
UDI-DI code: 00619498003259
Serial Numbers:
Astral Ventilators-Serial number < 22241890149
PCBA Spare Parts via physical PCBA or Ventilator UI - Characters 2 8 < 2707658
PCBA Spare Parts in Box - Box serial number < 22241978070
Catalog Number: Astral 150
UDI-DI code: 00619498270033
Serial Numbers:
Astral Ventilator-Serial numbers < 22241440282
PCBA Spare Parts via physical PCBA or Ventilator UI - Characters 2 8 < 2707658
PCBA Spare Parts in Box - Box serial number < 22241978070 |
| FEI Number |
3004604967
|
Recalling Firm/ Manufacturer |
ResMed Ltd. 1 Elizabeth Macarthur Dr Bella Vista Australia
|
Manufacturer Reason for Recall | Due to a Supercapacitor electrolyte leakage on Printed Circuit Board Assembly (PCBA) may damage the charger chip, causing fail-safe state and interruption of ventilation therapy. |
FDA Determined Cause 2 | Component design/selection |
| Action | ResMed Urgent Medical Device Correction Astral 100/150 Ventilators
Issue Identified: On June 25, 2026, ResMed notified customers via Salesforce of an urgent medical device correction involving a subset of Astral 100 and Astral 150 ventilators. An internal supercapacitor may leak electrolyte over time, potentially damaging the printed circuit board assembly (PCBA) and causing the ventilator to enter a fail-safe state.
Interim Guidance: Due to limited PCBA replacement availability, immediate correction of all affected units is not feasible. Physicians and patients are advised to follow Astral 100/150 User and Clinical Guides, including recommendations on monitoring, emergency preparedness, caregiver training, and backup ventilation.
Required Actions for Healthcare Providers and Distributors:
Acknowledge: Complete and return the acknowledgment form by July 31, 2026.
Notify: Distribute the correction notice and accompanying letters to all relevant healthcare professionals, patients, and caregivers immediately.
Reinforce Safety Measures: Ensure ventilator-dependent patients are monitored, caregivers are trained in alarm response and emergency procedures, and backup ventilation equipment is functional and readily available.
Device Management: Do not remove an affected ventilator from use unless an alternative is immediately available. Replace inoperable units promptly; patients should continue therapy unless directed otherwise by their clinician.
Risk Assessment: Evaluate affected patients by clinical risk category (Tier 1, 2, or 3) per Appendix A.
Arrange Inspection: Schedule ventilator inspections per the Phase 1 Inspection and Correction Strategy in Appendix A, returning units to an authorized service center as needed.
Contact: Reach your local ResMed representative or visit www.resmed.com/contact for questions. |
| Quantity in Commerce | 168,069 devices globally |
| Distribution | Worldwide - U.S. Nationwide distribution including in the states of AK, AL, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, and WY. The countries of Algeria, Argentina, Australia, Austria, Bahrain, Bangladesh, Belgium, Bhutan, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Finland, France, French Guiana, French Polynesia, Germany, Great Britain, Greece, Guadeloupe, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Islamic Republic of Iran, Israel, Italy, Japan, Jordan, Kenya, Republic of Korea, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Maldives, Malta, Martinique, Mauritius, Mexico, Morocco, Myanmar, Nepal, Netherlands, New Caledonia, New Zealand, Norway, Oman, Pakistan, Panama, Peru, Philippines, Poland, Portugal, Qatar, Reunion, Romania, Saint Martin (French part), Saudi Arabia, Singapore, Slovenia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, United Arab Emirates, Uruguay, and Viet Nam. |
| Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes.
|
| 510(K) Database | 510(K)s with Product Code = CBK
|
|
|
|